Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Immunohorizons ; 8(1): 1-18, 2024 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-38169549

RESUMO

Despite treatment advances, acute kidney injury (AKI)-related mortality rates are still high in hospitalized adults, often due to sepsis. Sepsis and AKI could synergistically worsen the outcomes of critically ill patients. TLR4 signaling and mitochondrial antiviral signaling protein (MAVS) signaling are innate immune responses essential in kidney diseases, but their involvement in sepsis-associated AKI (SA-AKI) remains unclear. We studied the role of MAVS in kidney injury related to the TLR4 signaling pathway using a murine LPS-induced AKI model in wild-type and MAVS-knockout mice. We confirmed the importance of M1 macrophage in SA-AKI through in vivo assessment of inflammatory responses. The TLR4 signaling pathway was upregulated in activated bone marrow-derived macrophages, in which MAVS helped maintain the LPS-suppressed TLR4 mRNA level. MAVS regulated redox homeostasis via NADPH oxidase Nox2 and mitochondrial reverse electron transport in macrophages to alleviate the TLR4 signaling response to LPS. Hypoxia-inducible factor 1α (HIF-1α) and AP-1 were key regulators of TLR4 transcription and connected MAVS-dependent reactive oxygen species signaling with the TLR4 pathway. Inhibition of succinate dehydrogenase could partly reduce inflammation in LPS-treated bone marrow-derived macrophages without MAVS. These findings highlight the renoprotective role of MAVS in LPS-induced AKI by regulating reactive oxygen species generation-related genes and maintaining redox balance. Controlling redox homeostasis through MAVS signaling may be a promising therapy for SA-AKI.


Assuntos
Injúria Renal Aguda , Sepse , Humanos , Animais , Camundongos , Lipopolissacarídeos , Espécies Reativas de Oxigênio/metabolismo , Receptor 4 Toll-Like/metabolismo , Injúria Renal Aguda/induzido quimicamente , Injúria Renal Aguda/metabolismo , Sepse/metabolismo
2.
Front Psychol ; 14: 1225122, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38111870

RESUMO

Challenge based learning is not generally considered part of positive education. This study argues that challenge based learning should be considered and integrated with positive education to advance it from three perspectives. First, the aims of both educational approaches emphasize the promotion of engagement, meaning, achievement, and learning. Second, empirical studies suggest that challenge based learning is likely to enhance well-being and learning outcomes, aligning with positive education's impact. Third, incorporating challenge based learning in positive education will likely address multiple criticisms of positive education and help advance it by incorporating real-life challenges, meaningful contexts, experiential learning, collective perspectives, and educational studies. To advance positive education, more empirical studies should be conducted on the impact of challenge based learning on well-being to fill the research gap in quantity, scope of variables, and longitudinal studies, with due consideration of its variety in implementation. Furthermore, innovative integration of challenge based learning and existing positive education interventions should be explored based on comparative analyses of both approaches to develop positive education that enables learners to flourish with challenges at the individual and collective levels. Positive education that explicitly incorporates challenges is called the positive education of challenge. To advance the positive education of challenge, more educational approaches (other than challenge based learning) that focus on challenges (e.g., challenge courses and pedagogy of challenge) should also be explored for integration with positive education.

3.
Clin Ther ; 45(9): 889-893, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-37487866

RESUMO

PURPOSE: Several D-amino acids have been shown to be protective against kidney injury in mice. Risperidone, a currently used atypical antipsychotic agent for schizophrenia, is also known to inhibit the activity of D-amino acid oxidase, which degrades certain D-amino acids. Based on the hypothesis that risperidone would prevent kidney disease progression, this study investigated the association between risperidone use and kidney function decline in patients with schizophrenia. METHODS: This retrospective cohort study included patients who were diagnosed with schizophrenia and had data available from two or more serum creatinine measurements between April 1, 2010, and March 31, 2020. Patients who used risperidone for at least 30 days were included in the risperidone group, whereas those who had no record of risperidone use were included in the control group. Cox regression models were used to evaluate the risk for 40% decline in estimated glomerular filtration rate (eGFR) in patients treated with risperidone compared to that in the control group. FINDINGS: Overall, 212 patients used risperidone and 1468 patients had no record of risperidone use. The mean age was 55 years, 759 (45%) of the patients were male, and the mean eGFR at baseline was 88 mL/min/1.73 m2. The mean age in the risperidone group was less than that in the control group (52 vs 56 years); other baseline characteristics were comparable between the two groups. During a mean follow-up of 1.6 years, 267 patients (16%) had a 40% eGFR decline. The incidence rate of 40% eGFR decline was lower in the risperidone group than in the control group (60 vs 104 per 1000 person-years). After adjustment for baseline age, sex, and eGFR, risperidone use was associated with a decreased risk for 40% eGFR decline (hazard ratio = 0.54; 95% CI, 0.33-0.87; P = 0.01). IMPLICATIONS: Risperidone use may be associated with decreased risk for kidney function decline in patients with schizophrenia. Further studies are warranted to validate these findings.


Assuntos
Antipsicóticos , Insuficiência Renal Crônica , Esquizofrenia , Humanos , Masculino , Animais , Camundongos , Pessoa de Meia-Idade , Feminino , Esquizofrenia/tratamento farmacológico , Risperidona/efeitos adversos , Estudos Retrospectivos , Antipsicóticos/efeitos adversos , Rim , Taxa de Filtração Glomerular
4.
FASEB J ; 37(7): e23005, 2023 07.
Artigo em Inglês | MEDLINE | ID: mdl-37289107

RESUMO

Fibroblast accumulation and extracellular matrix (ECM) deposition are common critical steps for the progression of organ fibrosis, but the precise molecular mechanisms remain to be fully investigated. We have previously demonstrated that lysophosphatidic acid contributes to organ fibrosis through the production of connective tissue growth factor (CTGF) via actin cytoskeleton-dependent signaling, myocardin-related transcription factor family (MRTF) consisting of MRTF-A and MRTF-B-serum response factor (SRF) pathway. In this study, we investigated the role of the MRTF-SRF pathway in the development of renal fibrosis, focusing on the regulation of ECM-focal adhesions (FA) in renal fibroblasts. Here we showed that both MRTF-A and -B were required for the expressions of ECM-related molecules such as lysyl oxidase family members, type I procollagen and fibronectin in response to transforming growth factor (TGF)-ß1 . TGF-ß1 -MRTF-SRF pathway induced the expressions of various components of FA such as integrin α subunits (αv , α2 , α11 ) and ß subunits (ß1 , ß3 , ß5 ) as well as integrin-linked kinase (ILK). On the other hand, the blockade of ILK suppressed TGF-ß1 -induced MRTF-SRF transcriptional activity, indicating a mutual relationship between MRTF-SRF and FA. Myofibroblast differentiation along with CTGF expression was also dependent on MRTF-SRF and FA components. Finally, global MRTF-A deficient and inducible fibroblast-specific MRTF-B deficient mice (MRTF-AKO BiFBKO mice) are protected from renal fibrosis with adenine administration. Renal expressions of ECM-FA components and CTGF as well as myofibroblast accumulation were suppressed in MRTF-AKO BiFBKO mice. These results suggest that the MRTF-SRF pathway might be a therapeutic target for renal fibrosis through the regulation of components forming ECM-FA in fibroblasts.


Assuntos
Fibroblastos , Nefropatias , Fatores de Transcrição , Animais , Camundongos , Actinas/metabolismo , Fibroblastos/metabolismo , Fibrose , Fatores de Transcrição/genética , Fatores de Transcrição/metabolismo , Nefropatias/metabolismo , Nefropatias/patologia
5.
FASEB J ; 36(11): e22606, 2022 11.
Artigo em Inglês | MEDLINE | ID: mdl-36250931

RESUMO

Kinesin family member 26b (Kif26b) is essential for kidney development, and its deletion in mice leads to kidney agenesis. However, the roles of this gene in adult settings remain elusive. Thus, this study aims to investigate the role of Kif26b in the progression of renal fibrosis. A renal fibrosis model with adenine administration using Kif26b heterozygous mice and wild-type mice was established. Renal fibrosis and the underlying mechanism were investigated. The underlying pathways and functions of Kif26b were evaluated in an in vitro model using primary renal fibroblasts. Kif26b heterozygous mice were protected from renal fibrosis with adenine administration. Renal expressions of connective tissue growth factor (CTGF) and myofibroblast accumulation were reduced in Kif26b heterozygous mice. The expression of nonmuscle myosin heavy chain II (NMHCII), which binds to the C-terminus of Kif26b protein, was also suppressed in Kif26b heterozygous mice. The in vitro study revealed reduced expressions of CTGF, α-smooth muscle actin, and myosin heavy chain 9 (Myh9) via transfection with siRNAs targeting Kif26b in renal fibroblasts (RFB). RFBs, which were transfected by the expression vector of Kif26b, demonstrated higher expressions of these genes than non-transfected cells. Finally, Kif26b suppression and NMHCII blockage led to reduced abilities of migration and collagen gel contraction in renal fibroblasts. Taken together, Kif26b contributes to the progression of interstitial fibrosis via migration and myofibroblast differentiation through Myh9 in the renal fibrosis model. Blockage of this pathway at appropriate timing might be a therapeutic approach for renal fibrosis.


Assuntos
Rim , Cinesinas , Miofibroblastos , Animais , Camundongos , Actinas/genética , Actinas/metabolismo , Adenina/metabolismo , Colágeno/metabolismo , Fator de Crescimento do Tecido Conjuntivo/genética , Fator de Crescimento do Tecido Conjuntivo/metabolismo , Fibroblastos/metabolismo , Fibrose , Rim/metabolismo , Cinesinas/genética , Miofibroblastos/metabolismo , Cadeias Pesadas de Miosina/genética , Cadeias Pesadas de Miosina/metabolismo , Diferenciação Celular , Movimento Celular
6.
Front Psychol ; 13: 1090069, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36743637

RESUMO

Activities and processes involving challenges are a natural part of life for most people and are highlighted in times of rapid change and global issues. This article argues that more studies around activities and processes involving challenges should be conducted with a focus on the concept of challenge in the context of well-being and optimal functioning. The concept of challenge is important because it is explicitly embedded in many major themes of positive psychology and can be a key concept in creating perspectives and frameworks to connect and integrate multiple elements in positive psychology to promote advancements in the field. Studying activities and processes involving challenges is also important from the perspective of dialectically integrating the positive and negative elements encompassed in the concept of challenge. The article also proposes to label activities and processes involving challenges as "challengership" and that an interdisciplinary area to study "challengership" (named "challengership studies") should be created, which can collaborate with positive psychology for mutual development. The positive psychology of challenge/challengership is likely to provide opportunities for further advancement of positive psychology by creating more integrated knowledge of how to flourish when faced with challenges individually and collectively. The knowledge created in these areas can also be applied to education, coaching, and training at schools and organizations to meet the needs of the times, where skills of challengership should be considered trainable.

7.
BMC Nephrol ; 21(1): 416, 2020 09 29.
Artigo em Inglês | MEDLINE | ID: mdl-32993539

RESUMO

BACKGROUND: Minimal change disease (MCD) is one of the causes of idiopathic nephrotic syndrome in adults. The pathogenesis of proteinuria in MCD has not been fully understood. Recently, it has been reported that the receptor activator of nuclear factor-kappa B (RANK)/RANK ligand (RANKL) may contribute to the podocyte biology in kidney diseases. Denosumab is a human anti-RANKL monoclonal antibody used to treat osteoporosis. Here we report a case of MCD after denosumab administration. CASE PRESENTATION: A 59-year-old male without any episodes of proteinuria was given denosumab to treat osteoporosis. Two weeks after its administration, he noticed a foamy urine and bilateral pretibial edema. Laboratory tests revealed that he had severe proteinuria (15g/g Cr), hypoproteinemia (4.0g/dL), and hypoalbuminemia (1.5g/dL). Based on the results, he was diagnosed with nephrotic syndrome. The proteinuria selectivity index was 0.05, indicating selective proteinuria. Renal biopsy showed minor glomerular abnormality with less tubulointerstitial damage, and electron microscopy showed extensive foot process effacement, indicating MCD. With all these results, glucocorticoid therapy of 50mg/day prednisolone was started. After 4weeks of treatment, the urinary protein level remains high (3.1g/g Cr). Prednisolone therapy was continued, and the levels of proteinuria decreased gradually to the range of partial remission (1.2g/g Cr) with another 7weeks of prednisolone treatment, but complete remission was not achieved. CONCLUSIONS: This might be a case wherein RANKL inhibition is associated with the pathogenesis of MCD. Further studies will be needed to elucidate the causal relationship of RANK-RANKL signaling to the pathogenesis of MCD.


Assuntos
Conservadores da Densidade Óssea/efeitos adversos , Denosumab/efeitos adversos , Nefrose Lipoide/induzido quimicamente , Ligante RANK/antagonistas & inibidores , Conservadores da Densidade Óssea/uso terapêutico , Denosumab/uso terapêutico , Humanos , Rim/patologia , Masculino , Pessoa de Meia-Idade , Nefrose Lipoide/patologia , Osteoporose/tratamento farmacológico , Albumina Sérica/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...